Electrical Impedance Tomography, Thoracic Breath Sensor and Lung Ultrasound measurements of Neonates with Respiratory Distress Syndrome during surfactant administration

Mater Health0 个研究点目标入组 40 人开始时间: 2020年3月10日最近更新: 2020年3月16日

试验速览

暂无简介。

•Infants 26 0/7 to 31 6/7 weeks corrected gestational age (gestation at birth plus days since birth)
•Weight appropriate for gestational age at birth
•Age < 72 hours
•Currently on nCPAP with an FiO2 requirement <0.30
•Approval of treating medical and nursing staff for recruitment to relevant study arm
•Parent(s) or guardian able and willing to provide informed consent
•At least one parent or guardian aged 18 years or older at the time of consent
•Have not yet received a dose of surfactant

•Apgar score less than or equal to 5 at five minutes after birth
•Both parents of baby under 18 years of age (due to the complexities of obtaining consent).
•Prior instillation of surfactant
•Congenital anomaly or syndrome expected to have significant effect on cardio-respiratory function
•Other diseases interfering with cardiopulmonary functions (hydrops fetalis, toxoplasmosis, rubella, cytomegalovirus, herpes simplex)
•Known or suspected chromosomal abnormality
•Concomitant or expected treatment with inhaled nitric oxide
•Any infant with fragile skin where EIT belt placement or TBS placement may damage the skin.

发起方

Mater Health